Avoiding toxicity with lung radiation therapy: An IASLC perspective.

[1]  R. Mak,et al.  Major adverse cardiac event risk prediction model incorporating baseline cardiac disease, hypertension, and logarithmic left anterior descending coronary artery radiation dose in lung cancer (CHyLL). , 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  O. Riesterer,et al.  Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial. , 2021, The Lancet. Oncology.

[3]  J. Sonke,et al.  Delivered dose-effect analysis of radiation induced rib fractures after thoracic SBRT. , 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  James D. Murphy,et al.  Radiation Recall Pneumonitis After Treatment With Checkpoint Blockade Immunotherapy: A Case Series and Review of Literature , 2021, Frontiers in Oncology.

[5]  B. Yeap,et al.  Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial. , 2021, JAMA oncology.

[6]  B. Solomon,et al.  Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy , 2021, Journal of Cancer Survivorship.

[7]  R. Mak,et al.  Mean Heart Dose is an Inadequate Surrogate for Left Anterior Descending Coronary Artery Dose and the Risk of Major Adverse Cardiac Events in Lung Cancer Radiotherapy. , 2021, International journal of radiation oncology, biology, physics.

[8]  O. Arrieta,et al.  Radiation-induced lung injury: current evidence , 2021, BMC Pulmonary Medicine.

[9]  Yi-long Wu,et al.  Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  M. V. van Herk,et al.  Challenges in the target volume definition of lung cancer radiotherapy , 2020, Translational lung cancer research.

[11]  R. Mak,et al.  Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non-Small Cell Lung Cancer. , 2020, JAMA oncology.

[12]  M. Aznar,et al.  Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  N. Hardcastle,et al.  Single-arm prospective interventional study assessing feasibility of using gallium-68 ventilation and perfusion PET/CT to avoid functional lung in patients with stage III non-small cell lung cancer , 2020, BMJ Open.

[14]  W. Ryder,et al.  Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study , 2020, International journal of radiation oncology, biology, physics.

[15]  B. Jeremic,et al.  Radiation-induced lung toxicity – cellular and molecular mechanisms of pathogenesis, management, and literature review , 2020, Radiation Oncology.

[16]  Emily Lam,et al.  The impact of smoking on adjuvant breast cancer radiation treatment: A systematic review. , 2020, Cancer treatment and research communications.

[17]  M. V. van Herk,et al.  Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  J. Welsh,et al.  Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  D. Chang,et al.  Second cancer risk after primary cancer treatment with three‐dimensional conformal, intensity‐modulated, or proton beam radiation therapy , 2020, Cancer.

[20]  D. Thwaites,et al.  Particle therapy toxicity outcomes: A systematic review , 2020, Journal of medical imaging and radiation oncology.

[21]  A. Louie,et al.  Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial , 2020, BMC Cancer.

[22]  P. Illei,et al.  Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer. , 2020, Clinical lung cancer.

[23]  Saqalgghmnvh Rrdrarlrl,et al.  Report of the Chicago Charitable Eye and Ear Infirmary , 1860, The Chicago Medical Journal.

[24]  Harry J de Koning,et al.  Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. , 2020, The New England journal of medicine.

[25]  C. Benes,et al.  Radioresistance of KRAS/TP53‐mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo , 2020, International journal of cancer.

[26]  K. Forster,et al.  Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  B. Yaremko,et al.  Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial , 2019, BMC Cancer.

[28]  D. de Ruysscher,et al.  Radiation-Induced Lung Injury (RILI) , 2019, Front. Oncol..

[29]  A. Louie,et al.  Is the Importance of Heart Dose Overstated in the Treatment of Non-Small Cell Lung Cancer? A Systematic Review of the Literature. , 2019, International Journal of Radiation Oncology, Biology, Physics.

[30]  J. Chang-Claude,et al.  Multi-centre technical evaluation of the radiation-induced lymphocyte apoptosis assay as a predictive test for radiotherapy toxicity , 2019, Clinical and translational radiation oncology.

[31]  Michael Lock,et al.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial , 2019, The Lancet.

[32]  J. Lee,et al.  Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Tomas Kron,et al.  Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. , 2019, The Lancet. Oncology.

[34]  Xiaodong Yang,et al.  Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades , 2019, Cancer management and research.

[35]  F. Kong,et al.  Chest Wall Toxicity After Stereotactic Body Radiation Therapy: A Pooled Analysis of 57 Studies. , 2017, International journal of radiation oncology, biology, physics.

[36]  Ali Kamen,et al.  An image-based deep learning framework for individualizing radiotherapy dose. , 2019, The Lancet. Digital health.

[37]  E. Yorke,et al.  Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma? , 2018, International journal of radiation oncology, biology, physics.

[38]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[39]  F. de Vathaire,et al.  Review of risk factors of secondary cancers among cancer survivors. , 2018, The British journal of radiology.

[40]  C. Benes,et al.  TP53 mutation status: emerging biomarker for precision radiation medicine? , 2018, Oncoscience.

[41]  N. Hardcastle,et al.  Functional lung imaging in radiation therapy for lung cancer: A systematic review and meta-analysis. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[42]  C. Simone,et al.  Advances in proton therapy in lung cancer , 2018, Therapeutic advances in respiratory disease.

[43]  A. Louie,et al.  SUNSET: Stereotactic Radiation for Ultracentral Non-Small-Cell Lung Cancer-A Safety and Efficacy Trial. , 2018, Clinical lung cancer.

[44]  D. Landau,et al.  Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer , 2018, BMJ Open.

[45]  Tinsu Pan,et al.  Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study , 2018, Quality of Life Research.

[46]  Steven H. Lin,et al.  A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. , 2018, Critical reviews in oncology/hematology.

[47]  J. Douillard,et al.  Patterns of locoregional failure in locally advanced non-small cell lung cancer treated with definitive conformal radiotherapy: Results from the Gating 2006 trial. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[48]  R. Salgia,et al.  Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). , 2015, International journal of radiation oncology, biology, physics.

[49]  J. She,et al.  Blood-based biomarkers for precision medicine in lung cancer: precision radiation therapy. , 2017, Translational lung cancer research.

[50]  M. Socinski,et al.  Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[51]  W. Curran,et al.  Long-Term Results of RTOG 0617: A Randomized Phase 3 Comparison of Standard Dose Versus High Dose Conformal Chemoradiation Therapy +/- Cetuximab for Stage III NSCLC , 2017 .

[52]  J. Sonke,et al.  Heart dose associated with overall survival in locally advanced NSCLC patients treated with hypofractionated chemoradiotherapy. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[53]  A. Bezjak,et al.  Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial , 2017, The Lancet. Oncology.

[54]  Sara Ramella,et al.  Local Control and Toxicity of Adaptive Radiotherapy Using Weekly CT Imaging: Results from the LARTIA Trial in Stage III NSCLC , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[55]  Paul E Kinahan,et al.  Functional lung avoidance and response‐adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy , 2017, Medical physics.

[56]  M. Janssen-Heijnen,et al.  Effects of prehabilitation and rehabilitation including a home-based component on physical fitness, adherence, treatment tolerance, and recovery in patients with non-small cell lung cancer: A systematic review. , 2017, Critical reviews in oncology/hematology.

[57]  J. Sonke,et al.  Dose to heart substructures is associated with non-cancer death after SBRT in stage I-II NSCLC patients. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[58]  C. Faivre-Finn,et al.  Effect of accurate heart delineation on cardiac dose during the CONVERT trial. , 2017, The British journal of radiology.

[59]  A. Berman,et al.  Predicted Rate of Secondary Malignancies Following Adjuvant Proton Versus Photon Radiation Therapy for Thymoma. , 2017, International journal of radiation oncology, biology, physics.

[60]  R. Thomson,et al.  Implementing shared decision making in the NHS: lessons from the MAGIC programme , 2017, British Medical Journal.

[61]  Wei Chen,et al.  Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[62]  P. Xia,et al.  A Histologic Basis for the Efficacy of SBRT to the lung , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[63]  Jacob G. Scott,et al.  A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. , 2017, The Lancet. Oncology.

[64]  M. Socinski,et al.  Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  M. Janssen-Heijnen,et al.  Stage III Non-Small Cell Lung Cancer in the elderly: Patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[66]  Markus Alber,et al.  Adaptive radiotherapy for advanced lung cancer ensures target coverage and decreases lung dose. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[67]  R. Govindan,et al.  PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Jeffrey V Siebers,et al.  Benefits of adaptive radiation therapy in lung cancer as a function of replanning frequency. , 2016, Medical physics.

[69]  S. Kabus,et al.  The first patient treatment of computed tomography ventilation functional image-guided radiotherapy for lung cancer. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[70]  G. Sharp,et al.  A Contralateral Esophagus-Sparing Technique to Limit Severe Esophagitis Associated With Concurrent High-Dose Radiation and Chemotherapy in Patients With Thoracic Malignancies. , 2015, International journal of radiation oncology, biology, physics.

[71]  W. Curran,et al.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.

[72]  Grace Parraga,et al.  Functional lung avoidance for individualized radiotherapy (FLAIR): study protocol for a randomized, double-blind clinical trial , 2014, BMC Cancer.

[73]  Pranshu Mohindra,et al.  Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  J. Sonke,et al.  Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[75]  A. Huang,et al.  Improved targeting of cancer care for older patients: a systematic review of the utility of comprehensive geriatric assessment. , 2013, Journal of geriatric oncology.

[76]  J. Mariani,et al.  Cardiac complications of thoracic irradiation. , 2013, Journal of the American College of Cardiology.

[77]  Jeffrey D Bradley,et al.  Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. , 2013, International journal of radiation oncology, biology, physics.

[78]  V. Servois,et al.  Acute Radiation Pneumonitis in Non-small Cell Lung Cancer: Is Respiratory-gated Control Useful? Results of a French Prospective Randomized Study , 2012 .

[79]  Damien C Weber,et al.  QA makes a clinical trial stronger: evidence-based medicine in radiation therapy. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[80]  V. Bar-ad,et al.  Esophagitis, treatment-related toxicity in non-small cell lung cancer. , 2012, Reviews on recent clinical trials.

[81]  H. Thierens,et al.  Development of a multicomponent prediction model for acute esophagitis in lung cancer patients receiving chemoradiotherapy. , 2011, International journal of radiation oncology, biology, physics.

[82]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[83]  Jose Belderbos,et al.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  Jan-Jakob Sonke,et al.  Adaptive radiotherapy for lung cancer. , 2010, Seminars in radiation oncology.

[85]  T. Schultheiss,et al.  Radiation dose-volume effects in the spinal cord. , 2010, International journal of radiation oncology, biology, physics.

[86]  Joseph O. Deasy,et al.  Radiation DoseVolume Effects in the Lung , 2010 .

[87]  Annette Kopp-Schneider,et al.  4D-CT-based target volume definition in stereotactic radiotherapy of lung tumours: comparison with a conventional technique using individual margins. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[88]  David Boulware,et al.  A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. , 2009, International journal of radiation oncology, biology, physics.

[89]  Lech Papiez,et al.  Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  H. Møller,et al.  Radiation-induced malignancies following radiotherapy for breast cancer , 2004, British Journal of Cancer.

[91]  Marcel van Herk,et al.  Errors and margins in radiotherapy. , 2004, Seminars in radiation oncology.

[92]  Steven E Lipshultz,et al.  Radiation-associated cardiovascular disease. , 2003, Critical reviews in oncology/hematology.

[93]  John D Boice,et al.  Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. , 2002, Journal of the National Cancer Institute.

[94]  A. R. Marchese,et al.  Changes in the proportion of types I and III collagen in the left ventricular wall of patients with post-irradiative pericarditis. , 1996, Cardiovascular surgery.

[95]  R Mohan,et al.  Dose-volume histograms. , 1991, International journal of radiation oncology, biology, physics.